Tokyo, Japan

Chieko Seno

This inventor holds 4 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Nippon Kayaku Kabushiki Kaisha. Active years: 2002-2015.

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 32(Granted Patents)


Company Filing History:


Years Active: 2002-2015

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Chieko Seno: Innovator in Polymer Conjugates

Introduction

Chieko Seno is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of polymer conjugates, particularly in the development of compounds that enhance drug delivery systems. With a total of 4 patents, her work is recognized for its innovative approach to improving therapeutic effects.

Latest Patents

One of her latest patents is a polymer conjugate of folic acid or a folic acid derivative. This invention discloses a polymer conjugate that does not utilize an amide bond, ensuring chemical stability and an adequate drug release rate within living organisms. Another notable patent is a high-molecular weight conjugate of physiologically active substances. This invention allows for the release of medicaments without relying on enzymes in the body, which is expected to have beneficial therapeutic effects.

Career Highlights

Chieko Seno is associated with Nippon Kayaku Kabushiki Kaisha, where she continues to innovate in her field. Her research focuses on creating water-soluble conjugates that can significantly improve drug delivery and efficacy.

Collaborations

Some of her notable coworkers include Masayuki Kitagawa and Hisao Ekimoto, who contribute to her research endeavors and collaborative projects.

Conclusion

Chieko Seno's work in polymer conjugates represents a significant advancement in drug delivery systems, showcasing her innovative spirit and dedication to improving therapeutic outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…